戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ersonalize and optimize therapy (therapeutic drug monitoring).
2 chieved by real-time beta-lactam therapeutic drug monitoring.
3 tients had linezolid adjusted by therapeutic drug monitoring.
4 nt-of-care applications in therapeutic/abuse drug monitoring.
5 g strategies, and the absence of therapeutic drug monitoring.
6 ld facilitate remotely conducted therapeutic drug monitoring.
7 f medication, dose, follow-up intervals, and drug monitoring.
8 sing for clinical toxicology and therapeutic drug monitoring.
9 ts, in vivo tissue sampling, and therapeutic drug monitoring.
10 delivery, molecular imaging, and therapeutic drug monitoring.
11 amer-based sensors can be used for real-time drug monitoring.
12 al diagnosis or for personalized therapeutic drug monitoring.
13 ering a tool for pharmacodynamic therapeutic drug monitoring.
14 ce use variables associated with therapeutic drug monitoring.
15 ith bipolar disorder received no therapeutic drug monitoring.
16 e also observed in the access to therapeutic drug monitoring.
17 ntimicrobial synergy testing and therapeutic drug monitoring allowed for assessment of treatment adeq
18                                              Drug monitoring allows individualization of a patient's
19 ults emphasize the importance of therapeutic drug monitoring and appropriate adjustment of asparagina
20 linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory moni
21 uding biosensor-based, real-time therapeutic drug monitoring and computer-controlled, closed-loop con
22 ccurate multiple sclerosis disease-modifying drug monitoring and decision making in the routine clini
23 rategy that incorporates routine therapeutic drug monitoring and dose adjustment over current standar
24 ood is also highly important for therapeutic drug monitoring and in personalized medicine.
25 inetic variability by the use of therapeutic drug monitoring and include measurement of the risks of
26 ion in biosamples is crucial for therapeutic drug monitoring and overdose diagnosis.
27 determine the appropriate use of therapeutic drug monitoring and tacrolimus dose following completion
28  multiple applications in, e.g., therapeutic drug monitoring and toxicology.
29 ly suppressed, in settings where therapeutic drug monitoring and/or close viral load monitoring are f
30                              Costs contained drugs, monitoring and adverse events measured in US Doll
31 ent antibiotic plan, (8) perform therapeutic drug monitoring, and (9) discontinue antibiotic therapy
32 porate rapid fungal diagnostics, therapeutic drug monitoring, and clinical intervention teams.
33 entions to optimize utilization, therapeutic drug monitoring, and data analysis and reporting.
34  as an ideal probe for forensic application, drug monitoring, and point-of care-diagnosis.
35 al dosing and appropriate use of therapeutic drug monitoring are not yet fully understood.
36 ntimicrobial synergy testing and therapeutic drug monitoring assessed treatment adequacy.
37              Personalised EID by therapeutic drug monitoring can enable further extension of treatmen
38 tment with infliximab, proactive therapeutic drug monitoring, compared with standard therapy, did not
39 tions in bioreactors, environmental sensing, drug monitoring, controlled drug delivery, early disease
40  dosing software supplemented by therapeutic drug monitoring data should be embedded into daily pract
41                                  Therapeutic drug-monitoring data from the Swiss HIV Cohort Study (SH
42                                  Therapeutic drug monitoring did not reveal any clinically significan
43 oanalytical applications such as therapeutic drug monitoring, doping in sports, and pharmacological s
44 gs do not support routine use of therapeutic drug monitoring during infliximab induction for improvin
45  of wearable chemical sensors is therapeutic drug monitoring for drugs that have a narrow therapeutic
46  first example of individualized therapeutic drug monitoring for subjects upon intake of standard L-D
47 is a more precise way to conduct therapeutic drug monitoring for vancomycin relative to trough-only c
48  include when to start therapy and with what drugs, monitoring for response and toxic effects, specia
49                                  Therapeutic drug monitoring has been added to our ALL-11 protocol to
50  has the potential to complement therapeutic drug monitoring in achieving target blood concentrations
51           The role of infliximab therapeutic drug monitoring in acute severe ulcerative colitis (ASUC
52 those evaluating the role of MMF therapeutic drug monitoring in cardiac transplant recipients will be
53  fibre-based device for non-invasive lithium drug monitoring in interstitial fluid.
54 e real-world clinical utility of therapeutic drug monitoring in psoriasis.
55 etermine whether dosing based on therapeutic drug monitoring increases rate of remission and whether
56                                  Therapeutic drug monitoring is advised to guide dosing interval adju
57 d to identify whether infliximab therapeutic drug monitoring is associated with ASUC outcomes.
58            We investigated whether proactive drug monitoring is associated with higher rates of clini
59 is management, little is known about whether drug monitoring is associated with response rate.
60                                              Drug monitoring is crucial for providing accurate and ef
61 of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended.
62                                  Therapeutic drug monitoring is essential for dosing pharmaceuticals
63 diseases, cancer diagnostics and therapeutic drug monitoring is given, which enables the readers to i
64                                  Therapeutic drug monitoring is seen as a valuable tool to improve pa
65                                  Therapeutic drug monitoring may be a useful method to promptly ident
66                                  Therapeutic drug monitoring may be advantageous when the CNI or MMF
67 design, our results suggest that therapeutic drug monitoring may be considered among patients experie
68 The present study suggests that piperacillin drug monitoring might be necessary in the sickest patien
69 al feasibility for point-of-care therapeutic drug monitoring of antibiotics.
70                                  Therapeutic drug monitoring of fluconazole can be a valuable tool to
71 od offers a new strategy for the therapeutic drug monitoring of NOACs and may improve the safe use of
72 achieved without CNI drugs, when therapeutic drug monitoring of sirolimus is employed.
73                   The utility of therapeutic drug monitoring on rejection prophylaxis and treatment i
74 iateness of 125 as target ratio, therapeutic drug monitoring or dose adjustments might be indicated f
75 s are used for therapeutic immunosuppressive drug monitoring (pharmacokinetics, PK).
76 not decline after adoption of a prescription-drug monitoring program (0.27 percentage points; 95% con
77 elated overdose deaths included prescription drug monitoring program (PDMP) access, mandatory PDMPs,
78 ved from California's statewide prescription drug monitoring program (PDMP) and county-level socioeco
79  reporting IDU before and after prescription drug monitoring program (PDMP) mandates were implemented
80                                 Prescription drug monitoring program access policies showed similar r
81  In 2011, Florida established a prescription drug monitoring program and adopted new regulations for
82 dy examines the availability of prescription drug monitoring program data for research and whether th
83 s or more frequently and review prescription drug monitoring program data, when available, for high-r
84 ring pill counts, and reviewing prescription drug monitoring program data, when available.
85 udy used statewide Rhode Island Prescription Drug Monitoring Program data.
86 xamines the association between prescription drug monitoring program mandates and changes in opioids
87 indicators of implementation of prescription drug monitoring program use mandates.
88 ing data from medical examiner, prescription drug monitoring program, and opiate treatment program re
89        Use of urine drug tests, prescription drug monitoring programmes and close observation of beha
90                       Mandatory prescription drug monitoring programs and cannabis legalization have
91 prescription rate compared with prescription drug monitoring programs and laws (6-month step change,
92     These findings suggest that prescription drug monitoring programs can use machine learning classi
93 e possible, states have created prescription drug monitoring programs to collect records of scheduled
94 riginal data set of laws (e.g., prescription-drug monitoring programs), we examined the annual preval
95 stment for age, marital status, prescription drug monitoring programs, and use of other medications.
96 er resources, such as state-run prescription drug monitoring programs, are also available to many phy
97 validated pain screening tools, prescription drug monitoring programs, urine drug screens, opioid use
98  2001, interventions designed in response to drug-monitoring programs worldwide resulted in a reducti
99 European sample from a Norwegian therapeutic drug monitoring service (n = 417).
100       Study results suggest that therapeutic drug monitoring should begin early in pregnancy and that
101                                  Therapeutic drug monitoring showed subtherapeutic azole concentratio
102 right patient at the right dose, therapeutic drug monitoring solutions are necessary.
103 lore challenges and opportunities for future drug monitoring, surveillance, control, and public healt
104 S]) has challenged traditional approaches to drug monitoring, surveillance, control, and public healt
105 address the lack of a reliable point-of-care drug monitoring system in the market.
106 s of first-line drugs were below therapeutic drug monitoring targets.
107 s of first-line drugs were below therapeutic drug-monitoring targets.
108                                  Therapeutic drug monitoring (TDM) aid therapeutic decision making in
109 es (MTX-PG(1-5)) may be used for therapeutic drug monitoring (TDM) as MTX-PG is thought to mediate MT
110  electrochemical sensor enabling therapeutic drug monitoring (TDM) at home directly from a drop of bl
111 th the Monolix software based on therapeutic drug monitoring (TDM) data.
112              The availability of therapeutic drug monitoring (TDM) for ampicillin and ceftobiprole ha
113                                  Therapeutic drug monitoring (TDM) for biologic therapies in inflamma
114 litates using the DBS method for therapeutic drug monitoring (TDM) for improving the efficacy and saf
115                        Proactive therapeutic drug monitoring (TDM) has been proposed to improve outco
116                                  Therapeutic drug monitoring (TDM) has emerged as a strategy for trea
117 g biologic drugs, does proactive therapeutic drug monitoring (TDM) improve outcomes as compared with
118 various techniques available for therapeutic drug monitoring (TDM) in cancer patients treated with DO
119                The importance of therapeutic drug monitoring (TDM) in this population is also explore
120                                  Therapeutic drug monitoring (TDM) involves measuring drug levels in
121  Antibiotic optimisation through therapeutic drug monitoring (TDM) is a key strategy in tackling anti
122 herapeutic dosage range to which therapeutic drug monitoring (TDM) is applied.
123                 In such a trend, therapeutic drug monitoring (TDM) is especially crucial for patients
124                                  Therapeutic drug monitoring (TDM) is increasingly valuable for tailo
125                          Routine therapeutic drug monitoring (TDM) is necessary to facilitate Tac man
126 marker of treatment response but therapeutic drug monitoring (TDM) is yet to be implemented in routin
127  and clinically adjusted (CA) vs therapeutic drug monitoring (TDM) maintenance strategies in patients
128                                  Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) is w
129 d, Tong et al have reported that therapeutic drug monitoring (TDM) of asparaginase (ASP) activity lev
130                                  Therapeutic drug monitoring (TDM) of beta-lactam antibiotics is reco
131 ied and categorized as requiring therapeutic drug monitoring (TDM) or non-TDM.
132 activity assessment and reactive therapeutic drug monitoring (TDM) prior to changes in biologic thera
133                                  Therapeutic drug monitoring (TDM) provides valuable guidance for dos
134 ion of many drugs are needed for therapeutic drug monitoring (TDM) purposes in this context.
135 ts with TB from an international therapeutic drug monitoring (TDM) service.
136 rent groups of patients requires therapeutic drug monitoring (TDM) to ensure optimal therapy.
137 of TmAb treatment requires close therapeutic drug monitoring (TDM) to optimise dosage for individual
138 nalytical platforms that perform therapeutic drug monitoring (TDM) without relying on mAb specific re
139 able effort placed on vancomycin therapeutic drug monitoring (TDM), clinicians should recognize that
140                        Proactive therapeutic drug monitoring (TDM), consisting of individualized trea
141                        Proactive therapeutic drug monitoring (TDM), defined as individualized drug do
142                                  Therapeutic drug monitoring (TDM), genotype guided dosing, and chron
143 merged as an innovative tool for therapeutic-drug monitoring (TDM), making it an ideal candidate for
144                                  Therapeutic drug monitoring (TDM), which involves measurement of dru
145                                  Therapeutic drug monitoring (TDM), which involves measuring drug lev
146  infusion (CI) BLs and underwent therapeutic drug monitoring (TDM)-guided BL dosing adjustment within
147 leukemia are individualized with therapeutic drug monitoring (TDM).
148 rough were determined as part of therapeutic drug monitoring (TDM).
149 copy as point-of-care method for therapeutic drug monitoring (TDM).
150 making it an ideal candidate for therapeutic drug monitoring (TDM).
151 nical chemistry laboratories for therapeutic drug monitoring (TDM).
152 ed precision dosing, an advanced therapeutic drug-monitoring technique, to guide dose minimization.
153 s platform represents a paradigm for in vivo drug monitoring that we anticipate will have many applic
154 re, it is highly recommended for therapeutic drug monitoring to control the drug level.
155 rating solution used in standard therapeutic drug monitoring to detach the drug from the proteins tha
156 nfections, necessitating precise therapeutic drug monitoring to ensure efficacy and safety.
157 travenous busulfan combined with therapeutic drug monitoring to guide dosing improves outcomes after
158 viral susceptibility testing and therapeutic drug monitoring to identify the optimal treatment for ea
159                      Evidence on therapeutic drug monitoring to predict drug toxicity is scarce.
160         Future studies including therapeutic drug monitoring will need to determine the role of dosag
161 ganization (WHO) Programme for International Drug Monitoring with publicly available online adverse e
162 selection of antimicrobials, and therapeutic drug monitoring would provide a more individualized dosi

 
Page Top